Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma
Conditions: Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma Interventions: Drug: Pembrolizumab IV infusion Q3W, with daily oral Olaparib. Sponsors: National Cancer Centre, Singapore; Merck Sharp& Dohme LLC; National Medical Research Council (NMRC), Singapore Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Lymphoma | Merck | Oral Cancer | Research | Singapore Health | T-cell Lymphoma